EP0155252A2
Expired / Lapsed
EP
⏱️ 0.0 years remaining
Immunoreactive solid phase
Assignee: Pfizer Health AB
•
Filing: 1985-03-12
•
Granted: —
•
Expires: 2005-03-12
Abstract
Abstract A process for activating a solid polymer surface by radiation grafting of vinyl monomers having at least one functional group which can be bound to biologically active molecules, as well as a process for preparing an immunoreactive solid phase wherein said biologically active molecules are covalently bound to said functional groups on the polymer surface. The processes are characterized in that the polymer surface is grafted in solution in a chain transfer reducing solvent at a monomer concentration below 3% by weight when the vinyl monomer is 1-mono-or 1,1-disubstituted, whereby a very thin layer is obtained. The invention also refers to the activated solid phase, obtained by the activating process, for immobilizing biologically active molecules and an immunoreactive solid phase comprising said molecules. The immunoreactive solid phase to which an antigen or an antibody has been covalently bound can be used for quantitative or qualitative determination of antigen or antibody in an immunoassay.
Inventors
- 👤 Sven Göthe
- 👤 Anders Hult
- 👤 Gunnar Johansson
- 👤 Per Larsson
Bibliographic Details
Application Number
—
Jurisdiction
EP
Data Source
google_patents
Last Synchronized
2026-11-07 17:26
CPC Classifications
C; C08; C08J; C08J7/00; C08J7/12; C08J7/16; G; G01; G01N; G01N33/00; G01N33/48; G01N33/50; G01N33/53; G01N33/543; G01N33/544; G01N33/545
Claims Analysis
Total Claims: 15
Claim 1
Independent Claim
70 words
Process for activating a solid polymer surface by radiation grafting of vinyl monomers having at least one functional group, which group can be bound to biologically active molecules, characterized in that the polymer surface is grafted in solution in a chain transfer reducing solvent at a monomer concentration below 3 % by weight when the vinyl monomer is 1-mono-or 1,1-disubstituted in order to prevent homopolymerization and an uncontrolled autocatalytic reaction.
Claim 2
Dependent Claim
70 words
Process for activating a solid polymer surface by radiation grafting of vinyl monomers having at least one functional group, which group can be bound to biologically active molecules, characterized in that the polymer surface is grafted in solution in a chain transfer reducing solvent at a monomer concentration below 3 % by weight when the vinyl monomer is 1-mono-or 1,1-disubstituted in order to prevent homopolymerization and an uncontrolled autocatalytic reaction.
Claim 3
Dependent Claim
21 words
Process according to claim 1, characterized in that the monomer concentration can be arbitrary selected if the vinyl monomer is 1,2-substituted.
Claim 4
Dependent Claim
48 words
Activated solid phase for immobilizing biologically active molecules, comprising a polymer substrate to which functional groups, which can be bound to the biologically active molecules, have been surface grafted, characterized in that the polymer surface has been radiation grafted in accordance with claim 1 in a thin layer.
Claim 5
Dependent Claim
27 words
Activated solid phase according to claim 3, characterized in that the polymer substrate is a shaped plastic, such as polyethylene, polypropylene, polystyrene, polyvinyl chloride, polyester or polymethylmethacrylate.
Claim 6
Dependent Claim
89 words
Process for preparing an immunoreactive solid phase, comprising radiation grafting of vinyl monomers having at least one functional group to a solid polymer surface, and subsequent covalent binding of biologically active molecules to the functional groups by means of condensating agents and methods known per se, characterized in that the polymer surface is grafted in solution in a chain transfer reducing solvent at a monomer concentration below 3 % by weight when the vinyl monomer is 1-mono- or 1,1-disubstituted in order to prevent homopolymerization and an uncontrolled autocatalytic reaction.
Claim 7
Dependent Claim
89 words
Process for preparing an immunoreactive solid phase, comprising radiation grafting of vinyl monomers having at least one functional group to a solid polymer surface, and subsequent covalent binding of biologically active molecules to the functional groups by means of condensating agents and methods known per se, characterized in that the polymer surface is grafted in solution in a chain transfer reducing solvent at a monomer concentration below 3 % by weight when the vinyl monomer is 1-mono- or 1,1-disubstituted in order to prevent homopolymerization and an uncontrolled autocatalytic reaction.
Claim 8
Dependent Claim
34 words
Process according to claim 5, characterized in that an 1,2-substituted acrylic acid is radiation grafted to a polystyrene substrate, and a biologically active molecule is covalently bound by means cf a carbodiimide condensating agent.
Claim 9
Dependent Claim
37 words
Immunoreactive solid phase comprising a polymer substrate with surface grafted functional groups to which biologically active molecules have been covalently bound, characterized in that the immunoreactive solid phase has been prepared by the process of claim 5.
Claim 10
Dependent Claim
40 words
Immunoreactive solid phase comprising a polymer substrate to which an antigen or an antibody has been bound, characterized in that the antigen or antibody is covalently bound to functional groups which have been radiation surface grafted to the polymer substrate.
Claim 11
Dependent Claim
40 words
Immunoreactive solid phase comprising a polymer substrate to which an antigen or an antibody has been bound, characterized in that the antigen or antibody is covalently bound to functional groups which have been radiation surface grafted to the polymer substrate.
Claim 12
Dependent Claim
62 words
Immunoreactive solid phase according to claim 8, characterized in that the polymer substrate is a polystyrene or PVC microtiter plate or tube, to the inner surface of which has been grafted a functional group -COOH -OH or -NH 2 , to which an antigen or an antibody has been covalently bound by means of a carbodiimide and a glutaraldehyde condensating agent respectively.
Claim 13
Dependent Claim
38 words
Use of an immunoreactive solid phase comprising a polymer substrate with surface grafted functional groups to which an antigen or an antibody has been covalently bound for quantitative or qualitative determination of antigen or antibody in an immunoassay.
Claim 14
Dependent Claim
38 words
Use of an immunoreactive solid phase comprising a polymer substrate with surface grafted functional groups to which an antigen or an antibody has been covalently bound for quantitative or qualitative determination of antigen or antibody in an immunoassay.
Claim 15
Dependent Claim
58 words
Use of an immunoreactive solid phase according to claim 10, comprising a polystyrene microtiter plate or tube to the inner surface of which has been grafted a functional group-COOH, -OH or -NH 2 , to which an antigen or an antibody has been covalently bound, for quantitative or qualitative determination of antigen or antibody in an enzyme immunoassay.
References Cited (Backward Citations)
No citation records indexed.
USPTO Annuity & Maintenance Windows
Maintenance schedule is calculated for granted US utility patents.